Table 1. Evaluation of the viability (MTT assay), LDH release and IL-1α release in the EpiVaginal tissue model treated with M48U1 and/or tenofovir.
| Viability (%) | LDH release (Abs) | IL-1α Release (pg/mL) | |
|---|---|---|---|
| Untreated (1 hour) | 100 + 5 | 0.211 ± 0.02 | 7.9 ± 0.9 |
| 20 μM tenofovir/0.25% HEC (1 hour) | 95 + 4 | 0.207 ± 0.06 | 7.8 ± 0.8 |
| 6.7 μM M48U1/0.25% HEC (1 hour) | 98 + 6 | 0.222 ± 0.05 | 8.0 ± 1.0 |
| 20 μM tenofovir + 6.7 μM M48U1/0.25% HEC (1 hour) | 97 + 5 | 0.218 ± 0.05 | 8.4 ± 0.7 |
| Untreated (4 hours) | 100 + 4 | 0.368 ± 0.05 | 9.7 ± 1.3 |
| 20 μM tenofovir/0.25% HEC (4 hours) | 96 + 6 | 0.381 ± 0.05 | 9.9 ± 1.8 |
| 6.7 μM M48U1/0.25% HEC (4 hours) | 98 + 7 | 0.364 ± 0.01 | 10.5 ± 1.1 |
| 20 μM tenofovir + 6.7 μM M48U1/0.25% HEC (4 hours) | 97 + 5 | 0.337 ± 0.01 | 10.3 ± 1.6 |
| Untreated (18 hours) | 100 + 8 | 1.179 ± 0.13 | 34.1 ± 2.6 |
| 20 μM tenofovir/0.25% HEC (18 hours) | 88 + 4 | 0.922 ± 0.2 | 36.5 ± 1.2 |
| 6.7 μM M48U1/0.25% HEC (18 hours) | 89 + 5 | 0.996 ± 0.2 | 33.8 ± 5.4 |
| 20 μM tenofovir + 6.7 μM M48U1/0.25% HEC (18 hours) | 91 + 6 | 1.103 ± 0.1 | 34.6 ± 4.2 |
| Untreated (96 hours) | 100 + 6 | 1.557 ± 0.08 | 61.9 ± 5.8 |
| 20 μM tenofovir/0.25% HEC (96 hours) | 104 + 9 | 1.498 ± 0.13 | 59.7 ± 7.7 |
| 6.7 μM M48U1/0.25% HEC (96 hours) | 91 + 7 | 1.544 ± 0.15 | 62.2 ± 9.3 |
| 20 μM tenofovir + 6.7 μM M48U1/0.25% HEC (96 hours) | 98 + 9 | 1.631 ± 0.21 | 64.0 ± 8.7 |